Androgen receptor (AR) signalling is essential to nearly all prostate cancer cells. Any alterations to AR-mediated transcription can have a profound effect on prostate carcinogenesis and tumour growth. While the AR protein has been extensively studied, little is know about mutations to the non-coding regions where AR binds to DNA. Using clinical whole genome sequencing, we demonstrate that AR binding sites have a dramatically increased rate of mutations that is greater than any other transcription factor and specific to only prostate cancer. Demonstrating this may be common to lineage-specific transcription factors, estrogen receptor binding sites had an elevated rate of mutations in breast cancer. Based on the mutations observed at the binding site of AR and other related transcription factors, we proposed that AR occupancy impairs access of base excision repair enzymes to endogenous DNA damage. Overall, this work demonstrates that non-coding AR binding sites are frequently mutated in prostate cancer and may potentially act as driver mutations.
shortened telomeres [24] . In PCa, a non-coding mutation to a polymorphic regulatory element was identified that impacted the regulation of DNA repair and hormone-regulated transcript levels in SPOP mutant patients [25] . Given their potential role in modifying the regulatory landscape of PCa, a better understanding of non-coding mutations is critical for more effective treatments.
While AR has been previously shown to induce DNA damage in vitro, the relatively low frequency of somatic mutations in PCa (~1 SNV/Mb) has prevented the study of TF-mediated DNA damage in clinical samples. Therefore, using large-scale WGS data we investigated how TF binding affects somatic mutations in PCa [26] . Interestingly we found that AR occupancy causes a high level of somatic mutations at the DNA binding sites. The mutations observed at these binding sites was very different than the remainder of the genome.
RESULTS

AR binding sites have a markedly higher rate of mutations in PCa
To investigate the impact of TF binding on non-coding somatic mutations, we initially quantified the mutational density at binding sites using WGS of primary PCa (n=196) from the Pan Cancer Analysis of Whole Genome (PCAWG). TF binding sites were obtained from ChIP-seq of a single prostate cancer cell line (LNCaP), as very few studies have been done using clinical samples. DNA hypersensitive sites (DHS) were included as a negative control, as DHS were shown to have a lower rate of somatic mutations due to increased access of DNA repair machinery [27] . When we compared the mutational rate at TF binding sites to randomly shuffled regions in PCa, many TF binding sites including HOXB13, EP300, SUZ12 were found to have a statistically higher rate of mutations (FDR=0; Figure 1 ). As expected, DHS had a much lower rate of mutations than either any other TF or random regions. Contrasting earlier work in both colorectal cancer [5] and melanoma [7] , CTCF binding sites did not have an increased rate of mutations as compared to either random regions or regions nearby the TF binding site (Supplementary Figure 1A) . However of all the TF's characterized, AR binding sites were found to have the highest rate of somatic mutations. To confirm that was not an artifact of using binding site data from a cell line, we observed an even greater mutational rate at ARBS that were identified from ChIP-seq of clinical PCa samples (Figure 1) . A similar trend was observed with indels at ARBS in PCa, though not as dramatic due to the low numbers of indels obtained by consensus mutation calling (Supplementary Figure 1B) . The increase in ARBS mutations is not likely due to epigenetic modifications as ARBS had greater than twice the mutation rate of regions with H3K27Ac, H3K4me3, H3K4me1 or H3K36me3 marks.
AR provides an ideal model to study TF-mediated mutations as this nuclear receptor is critical to the growth of nearly all PCa tumours, but is not active or required in other cancers. Thus, the ARBS chromosomal locations should not have increased mutations in other cancers if the observed results are due to AR binding rather than regional DNA instability. When we calculated the rate of mutations at ARBS from whole genome sequencing of over 20 different cancer types (n=2576) the rate of SNV mutations at ARBS was greater in PCa than either all other cancers (Wilcox t-test; p<2x10 -16 ) or any individual cancer (Figure 2A) . Importantly, no other cancer other than PCa had a higher rate of SNVs at ARBS than random regions (Supplementary Figure 2 ). An increase in mutations at ARBS was clearly observed in PCa, but not other cancers, with a enrichment approximately ±375bp from the maximal AR peak ( Figure 2B ). This was not due to nucleotide composition, as those regions that have an ARE motif but no bound AR did not have an increase in SNVs or indels ( Figure 2C ). Providing further confidence that these mutations occur due to AR occupancy, we observed a clear correlation between SNV density and ChIP-seq peak height ( Figure 2C) . Overall these results demonstrate that AR binding correlates with an increase in somatic mutations.
To determine if a similar increase in mutations was observed with other lineage-specific TFs, we quantified the rate of SNV mutations at Estrogen Receptor binding sites (ERBS) in breast cancer (Supplementary Figure 3) . Similar to what we observed at ARBS in PCa, breast cancer had the highest rate of mutations at ERBS. While not the goal of this work, it does suggest that TF binding site mutations are cell-of-origin specific.
We then looked to determine if the ARBS mutations occurred at those regions with specific epigenetic modifications or TF binding co-occupancy. This was based on previous literature which demonstrated that the cellular epigenetic state could dramatically alter the mutational rate
[2]. However, despite extensive optimization no relationship could be observed between ARBS mutations and specific histone marks or TF co-occupancy (Supplementary Figure 4) . As we do not have binding information for all possible histone marks or TF there may yet be an undiscovered correlation. However, our current data suggests that ARBS mutations do not correlate with specific epigenetic modification or proteins and are solely due to AR binding.
AR-mediated SNV mutations induce purine transversions
To better understand the cause of these mutations, we then determined the mutational signature at ARBS. While these binding sites only represents a small portion of the total genome (~100Kb), the mutational signature of a large region should be roughly the same as the whole genome if there is a sufficient number of mutations. Supporting this, we found that random regions with a similar size or nucleotide composition to ARBS almost always had a near identical mutational signature to the PCa genome (Supplementary Figure 5A) . Further, the number of SNVs observed at ARBS are well over the previously calculated minimum threshold to decipher a mutation signatures with >95% accuracy [28] . Interestingly, when we looked at the mutations at ARBS in PCa we found a dramatically different mutational profile than the remainder of the cancer genome ( Figure 3A) . Specifically, there was an increase in TpG->ApG and CpG->GpG purine transversions. These infrequent mutations occur at a much lower rate in the remainder of the PCa genome. Demonstrating that this was not due to the nucleotide composition, those regions of the chromosome that have an ARE motif but no AR binding did not have the same type of mutations ( Figure 3A) . When we shuffled chromosomal locations to match the nucleotide composition of ARBS and recalculated the mutational signature, no random regions were found to have mutational signatures comparably enriched for TpG ->ApG (Supplementary Fig 5B) . We observed no difference in either the rate or type of mutation if the ARBS had a canonical ARE (Wilcoxon signed rank test p=0.97; Supplementary Fig 6) . Finally, to test if the mutations were due to the specific chromosomal locations where AR binds we compared the mutational signatures at ARBS in all cancer types ( Figure 3B ). Only PCa was found to have a different mutation type at ARBS. All others cancers, which do not express or require AR, had the same signature at both the ARBS and whole genome. This demonstrates that the observed ARBS mutational signature was not caused by differences in nucleotide composition or chromosomal characteristics and is due to AR binding.
Having observed an AR-specific mutational signature, we tested if other TF binding sites had similar types of mutations. If these were directly caused by AR binding, only ARBS would be expected to have this signature. We therefore analyzed all TFs that had both an increased rate of mutations ( Figure 1 ) and a total number of mutations that was greater than the previously published theoretical threshold [28] . When the TF mutation signatures were compared, we found three distinct signature types ( Figure 3C) . First, KDM1A, HOXB13 and GATA2 were found to have a very similar mutational signature to AR ( Figure 3D ). This correlation was not due to an co-occupancy of the binding sites as a similar result was obtained even after removing regions that overlap with the AR (Supplementary Figure 7A+B) . Further, it was not due to the nucleotide composition of these regions as those site with AR, GATA2 or HOXB13 motifs but no protein (motif alone) did not have either an increased rate of mutations or a change in the mutation type (Supplementary Figure 7A+B) . These mutation types were only observed in PCa and were not seen in other cancer types (Supplementary Figure 7C) . Second, members of the polycomb repressive complex 2 (PRC2) including SUZ12 and EZH2 had a very different mutational signatures than any other TF. As before, these mutations were not due to simple overlap of the binding sites (Supplementary Figure 8A) . However, these specific mutations
were not only seen in PCa. We also observed a similar mutational signature at SUZ12/EZH2
binding sites in several other cancer types (Supplementary Figure 8B) . Finally, the remaining TFs including POLR2A and CTBP1 had a complicated mutational signature that was much closer to the whole genome than the other TFs. Importantly, the observed mutational signatures were not solely due to nucleotide composition as POLR2A, which has a similar GC content to SUZ12 and EZH2, had a very different mutational signature (Supplementary Figure 9) .
To identify the potential etiological factor of the TF-mediated mutations we compared our results to previously published mutational signatures [1] . Demonstrating the utility of this method, there was a striking similarity between SUZ12/EZH2 binding sites and a previously published COSMIC mutational signature (Signature 1; Figure 4A ). This well characterized signature has been reported in numerous cancer types and is caused by spontaneous deamination of 5-methylcytosine. Supporting this hypothesis almost all C->T mutations in SUZ12/EZH2 binding sites were found to occur at CpG sites (Supplementary Figure 8C) . Further, when we looked at genome-wide bisulfite sequencing, SUZ12/EZH2 had some of the highest levels of DNA methylation of all the TF binding sites (Supplementary Figure 8D) . Having shown the effectiveness of this approach, we then investigated the mutation type at ARBS and KDM1A/HOXB13/GATA2 binding sites. However, the ARBS mutations were very different than COSMIC mutational signatures and no published signature, excluding that caused by aristolochic acid, had a high frequency of TpG-> ApG mutations ( Figure 3A) . 
DISCUSSION
Cancer is a disease of genetic errors. Through it's mutations, we can begin to understand the molecular underpinnings of the malignant state. These mutations are not evenly distributed through the genome and are affected by numerous variables. There is emerging evidence that the rate of somatic mutations is higher at TF binding sites [5] [6] [7] . This has been demonstrated in two cancer types that have very high rates of mutations (~100 SNV/MB), as only a small number of patients is needed to provide sufficient statistical power. indel=Snowman, SNV=Mutect). Only those mutations which had been called by two or more callers and not found in dbSNP(v147) were used in this work.
Transcription factor binding sites
ChIP-seq data was obtained for the following published work: FOXA1(GSM1410788),
AR(GSE83860), H3K9ME3(GSM353610), H3K4ME1(GSM1410780), H3K4ME3(ENCODE:
ENCFF401MDR), H3K27AC(GSM1249448), H3K36ME3(GSM875814). Clinical ARBS were identified from AR ChIP-seq of 13 tumour and 7 normal human tissue samples (GSE70079).
Overlapping peaks were identified by HOMER's (v4.7) mergePeaks function (-d parameter 200)
[38]. All binding sites that overlapped with UCSD blacklisted regions were removed.
Motif driven peaks were predicted by PWMtools with given positional weight matrixes obtained from JASPAR DB.
Determination of intersecting regions
Bedtools (version 2.26.0) and bedops (version 2.4.26) were used to intersect, manipulate and filter specific regions in bed and vcf files [39] . To extend binding regions bedtools slop function was used. For intersection and filtration, we used bedtools intersect and bedops bedmap function.
Comparing specific region mutation frequency with background
Bedtools shuffle function was used to generate randomized regions across the genome. Each bed file was randomized 1000 times to generate a null distribution. All gapped regions (UCSC gapped regions) were removed. To generate random bed files with similar base composition (ATCG) of each random region we extensively randomized the AR binding data and then calculated base composition. We then z normalized each nucleotide type columns identify those random bed files similar to ARBS 250 bed file (as null value). The peak files which have the base composition that are in the ± 2 standard deviation (sd) range were selected.
Mutation Signature Analysis
Mutation signature analysis was done using the bioconductor package SomaticSignature (version AR ChIP-seq peaks were divided into quartiles based on peak height (low/low-medium/mediumhigh/high). A clear correlation was observed between peak height and increased SNVs at ARBS. The normalized rate of SNVs at ERBS was compared in multiple cancers. Breast cancer has found to have the highest rate of SNVs at these binding sites.
Supplementary Figure 4:
ARBS mutations were clustered with all other histone marks and TFs. No correlation was observed between the ARBS SNV and specific epigenetic marks or TF binding.
Supplementary Figure 5:
The mutational signature at ARBS is not due to nucleotide composition. (A) The mutational signature of PCa whole genome was compared against randomized regions (n=1000) that the same size as ARBS (~100k Kb). Randomized regions that had a matched nucleotide composition to the ARBS were subsetted (yellow). The mutational signature of the whole genome was extremely similar to the smaller randomized regions with a median cosine similarity of 0.953.
(B) ARBS were found to have a higher frequency of all T->A or TpG->ApG transversion than randomized regions with a matched nucleotide composition.
Supplementary Figure 6:
The frequency and type of ARBS mutations were not impacted by the presence of a canonical Androgen Response Element (ARE) motif. 
Supplementary Figure 9:
The GC and AT nucleotide composition was calculated at all TF binding sites, histone marks and regions that contain specific TF motifs. 
